
Study Period | 2019 - 2030 |
Market Size (2025) | USD 90.78 Billion |
Market Size (2030) | USD 97.41 Billion |
CAGR (2025 - 2030) | 1.42 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
Preventive Vaccines Market Analysis
The Preventive Vaccines Market size is estimated at USD 90.78 billion in 2025, and is expected to reach USD 97.41 billion by 2030, at a CAGR of 1.42% during the forecast period (2025-2030).
The global vaccine market continues to evolve rapidly, driven by significant technological advancements and changing healthcare priorities. The industry has witnessed a fundamental shift toward more sophisticated and efficient vaccine development methodologies, with particular emphasis on genetic engineering and proteomics. According to the World Health Organization's latest data, the burden of infectious diseases remains significant, with Southeast Asia accounting for 43% of tuberculosis cases, followed by Africa at 25% and the Western Pacific region at 18%, highlighting the continued importance of preventive vaccination programs worldwide.
The manufacturing and distribution infrastructure for prophylactic vaccines has undergone substantial transformation, with companies investing heavily in modernizing their production facilities and adopting advanced technologies. This evolution has been particularly evident in the development of novel delivery systems and formulation techniques. For instance, in October 2022, Shanghai implemented an innovative approach to vaccine administration by initiating booster vaccination through inhalation for adults aged 18 and above, demonstrating the industry's move toward more patient-friendly delivery methods.
The regulatory landscape for preventive vaccines has become increasingly sophisticated, with authorities worldwide implementing more stringent quality control measures while simultaneously working to expedite approval processes for critical vaccines. Recent WHO data indicates that approximately 58 million people globally have chronic hepatitis C virus, with about 1.5 million new infections occurring annually, emphasizing the need for continued regulatory support in vaccine development and distribution. This has led to enhanced collaboration between regulatory bodies and vaccine manufacturers to ensure both safety and accessibility.
The vaccines market has witnessed significant evolution in research and development approaches, with a growing focus on personalized medicine and targeted vaccination strategies. Pharmaceutical companies are increasingly investing in biotechnology and genetic engineering capabilities to develop more effective and safer vaccines. The industry has also seen a marked shift toward sustainable manufacturing practices and environmentally conscious production methods, reflecting broader healthcare industry trends toward sustainability and responsible manufacturing. The vaccine market forecast indicates continued growth, driven by these innovative approaches and the increasing demand for effective preventive solutions.
Preventive Vaccines Market Trends
Rising Prevalence of Infectious Diseases
The increasing burden of various infectious diseases worldwide has become a significant driver for the preventive vaccine market. According to the World Health Organization's 2022 data, approximately 58 million people have chronic hepatitis C virus infection globally, with about 1.5 million new infections occurring annually. Additionally, an estimated 296 million people were living with chronic hepatitis B infection, highlighting the critical need for prophylactic vaccines measures. The prevalence of these diseases, particularly among children and adolescents, has led to an increased focus on vaccination programs, with an estimated 3.2 million children and adolescents affected by chronic hepatitis C infection worldwide.
The emergence of new infectious diseases and the resurgence of existing ones have further emphasized the importance of disease prevention vaccines. For instance, according to the National Foundation for Infectious Diseases (NFID) data from March 2022, approximately 150,000 people are hospitalized annually due to pneumococcal pneumonia in the United States, with a mortality rate of 5-7% among the general population and even higher rates among elderly patients with underlying conditions. The substantial disease burden and associated healthcare costs have prompted healthcare authorities and governments to strengthen their vaccination programs, driving the demand for preventive vaccines across various disease categories.
Innovative Technology in Vaccine Development
The advancement in vaccine development technologies has revolutionized the human vaccines market, particularly through the introduction of genetic engineering, vaccine delivery technology, and proteomics. The emergence of mRNA technology has opened new possibilities for vaccine development, offering advantages such as minimal contamination from synthetic material use and in vitro development. These technological innovations have enabled the development of more effective and safer vaccines while significantly reducing production timelines and improving manufacturing efficiency.
Recent technological breakthroughs have led to the development of novel vaccine delivery methods, enhancing both efficacy and accessibility. For instance, in November 2022, Australia-based Vaxxas launched a Phase 1 clinical trial for a high-density microarray patch (HD-MAP) needle-free vaccine candidate at the University of Sunshine Coast's Sippy Downs. Similarly, in May 2022, the Coalition for Epidemic Preparedness Innovations (CEPI) granted USD 19.3 million to an international multidisciplinary consortium to support the development of a "variant-proof" SARS-CoV-2 vaccine candidate, demonstrating the industry's commitment to innovative vaccine technologies.
Increased Funding from Government and International Organizations
Government and international organization funding has emerged as a crucial driver for the vaccine research market, supporting research, development, and manufacturing initiatives. In July 2022, the Duke Human Vaccine Institute (DHVI) and the Department of Surgery at Duke University School of Medicine received a substantial grant from the National Institute of Allergy and Infectious Diseases for vaccine research, potentially totaling USD 25.9 million over five years. This significant investment demonstrates the commitment to advancing vaccine development and improving global health outcomes.
The establishment of international funding mechanisms has further accelerated vaccine development and accessibility. For instance, in February 2022, the United Kingdom pledged GBP 160 million to the Coalition for Epidemic Preparedness Innovations (CEPI) to expedite vaccine development while encouraging international partners to support this vital work. Additionally, Biological E Ltd revealed expansion plans in July 2022, announcing an investment of approximately USD 2.2 billion to enhance vaccine manufacturing capacity in Hyderabad, focusing on various vaccines including tetanus and pertussis vaccines.
Increasing Focus of Governments on Immunization Programs
Governments worldwide have intensified their focus on immunization programs, recognizing vaccines as one of the most cost-effective public health interventions. According to the World Health Organization, immunization currently prevents 3.5-5 million deaths every year from diseases like diphtheria, tetanus, pertussis, influenza, and measles. This has led to the implementation of comprehensive national immunization programs across various countries, with particular emphasis on reaching underserved populations and ensuring vaccine equity.
The expansion of immunization programs has been accompanied by increased awareness campaigns and improved healthcare infrastructure. For instance, in November 2022, in a move to eliminate Japanese encephalitis (JE), the Pune Municipal Corporation (PMC) launched an immunization drive targeting over 11 million children. Similarly, in June 2022, the Global Alliance for Vaccination and Immunization (Gavi) partnered with various governments to launch the Zero-dose Immunization Programme (ZIP), focusing on bringing healthcare to children in some of the world's most precarious frontier zones. These initiatives demonstrate the growing commitment of governments to strengthen their immunization programs and improve vaccine coverage rates.
Segment Analysis: By Vaccine Type
mRNA Vaccines Segment in Preventive Vaccines Market
The mRNA vaccines segment has emerged as the dominant force in the global preventive vaccines market, commanding approximately 48% of the market share in 2024. This substantial market position is driven by the segment's revolutionary approach to vaccine development, which has demonstrated remarkable efficacy in preventing infectious diseases. The segment's prominence is further strengthened by continuous technological advancements in mRNA platform technology, improved stability, translation, and delivery techniques. Major pharmaceutical companies are actively expanding their mRNA vaccine portfolios beyond COVID-19 to address other infectious diseases, including influenza and respiratory syncytial virus (RSV), which continues to solidify the segment's market leadership.

Live/Attenuated Vaccines Segment in Preventive Vaccines Market
The live attenuated vaccines market segment is projected to experience the most robust growth in the preventive vaccines market during 2024-2029, with an expected growth rate of approximately 10%. This impressive growth trajectory is attributed to the segment's ability to generate strong cellular and antibody responses that often confer lifelong immunity with just one or two doses. The segment's expansion is further supported by ongoing research studies, technological advancements in vaccine development, and new investments by companies and stakeholders. The development of novel delivery methods and improved formulations is enhancing the stability and efficacy of live/attenuated vaccines, making them increasingly attractive for both existing and emerging infectious diseases.
Remaining Segments in Vaccine Type
The preventive vaccines market encompasses several other significant segments, including inactivated vaccines, subunit vaccines, toxoid vaccines, and other specialized vaccine types. Inactivated vaccines continue to play a crucial role due to their safety profile and suitability for immunocompromised patients. Subunit vaccines are gaining traction due to their specific immune response targeting and reduced side effects. Toxoid vaccines remain essential for preventing diseases caused by bacterial toxins. Each of these segments contributes uniquely to the market's diversity, offering healthcare providers a comprehensive range of options to address various immunization needs and patient populations.
Segment Analysis: By Disease Type
COVID-19 Segment in Preventive Vaccines Market
The COVID-19 segment has emerged as the dominant force in the global preventive vaccines market, commanding approximately 71% market share in 2024. This substantial market position is driven by the continued need for COVID-19 vaccination programs worldwide, including primary doses and booster shots to combat emerging variants. The segment's prominence is reinforced by the extensive distribution networks established by major vaccine manufacturers and the ongoing support from government and international health organizations. The development and approval of new vaccine formulations, including bivalent and intranasal vaccines, has further strengthened this segment's market leadership. Additionally, the integration of COVID-19 vaccines into routine immunization programs and the focus on vulnerable populations has helped maintain its dominant position in the preventive vaccines landscape.
Influenza Segment in Preventive Vaccines Market
The influenza segment is demonstrating remarkable growth potential, with an expected CAGR of approximately 10% during the forecast period 2024-2029. This impressive growth trajectory is fueled by increasing awareness about seasonal flu prevention, expanding vaccination coverage across different age groups, and the development of more effective vaccine formulations. The segment's growth is further supported by technological advancements in vaccine development, including the exploration of mRNA-based flu vaccines and combination COVID-19/influenza vaccines. Government initiatives promoting annual flu vaccination programs, particularly for high-risk populations such as the elderly and healthcare workers, are also contributing to this segment's expansion. The continuous evolution of influenza strains necessitating regular vaccine updates and the growing emphasis on preventive healthcare are additional factors driving this segment's robust growth.
Remaining Segments in Disease Type Segmentation
The preventive vaccines market encompasses several other significant segments including pneumococcal, poliovirus, measles-mumps-rubella (MMR), hepatitis, and other disease types. The pneumococcal segment maintains its importance due to its critical role in preventing invasive pneumococcal diseases, particularly in children and elderly populations. The poliovirus segment continues to be vital in global eradication efforts, especially in endemic regions. The MMR segment remains crucial in childhood immunization programs worldwide, while the hepatitis vaccine market addresses both adult and pediatric populations. These segments collectively contribute to the market's diversity and reflect the comprehensive approach to disease prevention through vaccination. The continuous research and development efforts in these areas, coupled with expanding immunization programs and increasing healthcare awareness, ensure their sustained relevance in the global human vaccine market landscape.
Preventive Vaccines Market Geography Segment Analysis
Preventive Vaccines Market in North America
The North American preventive vaccines market size is supported by robust infrastructure and advanced healthcare systems across the United States, Canada, and Mexico. The region benefits from strong government support for immunization programs, extensive research and development activities, and the presence of major vaccine manufacturers. The well-established regulatory framework, high healthcare spending, and increasing focus on preventive healthcare contribute to market growth. The region's market dynamics are shaped by comprehensive vaccination programs, growing awareness about preventive healthcare, and continuous technological advancements in vaccine development.

Preventive Vaccines Market in United States
The United States dominates the North American preventive vaccines market size, holding approximately 82% market share in the region. The country's market leadership is driven by a robust healthcare infrastructure, substantial research and development investments, and the presence of major pharmaceutical companies. The U.S. Centers for Disease Control and Prevention (CDC) plays a crucial role in implementing nationwide immunization programs and maintaining high vaccination rates. The country's strong intellectual property protection, favorable reimbursement policies, and continuous focus on innovative vaccine technologies further strengthen its market position. The presence of well-established distribution networks and storage facilities ensures efficient vaccine delivery across the nation.
Growth Dynamics in United States Preventive Vaccines Market
The United States is projected to maintain its growth momentum with an expected CAGR of approximately 1% during 2024-2029. The growth is supported by increasing healthcare expenditure, rising awareness about preventive healthcare, and continuous government initiatives promoting vaccination programs. The country's strong pipeline of vaccine candidates, coupled with ongoing research in novel vaccine technologies, contributes to market expansion. The focus on developing next-generation vaccines and expanding vaccination coverage across different age groups further drives market growth. The presence of advanced cold chain infrastructure and efficient logistics networks supports the distribution of various types of vaccines across the country. This analysis is part of the broader global vaccine market report.
Preventive Vaccines Industry Overview
Top Companies in Preventive Vaccines Market
The preventive vaccines market is dominated by established pharmaceutical giants, including AstraZeneca, GSK, Johnson & Johnson, Merck, Pfizer, and Sanofi, alongside emerging players like Novavax and specialized vaccine manufacturers. These companies are heavily investing in research and development to advance vaccine technologies market, with a particular focus on mRNA platforms and novel delivery methods following the success of COVID-19 vaccines. The industry is characterized by strategic collaborations between pharmaceutical companies and research institutions to accelerate vaccine development timelines and enhance manufacturing capabilities. Companies are expanding their geographical presence through partnerships with local manufacturers and distributors, particularly in emerging markets. Product portfolio diversification, investment in cold chain infrastructure, and the development of combination vaccines have emerged as key competitive strategies, while digital transformation initiatives are being implemented to optimize production and distribution processes.
Consolidated Market with High Entry Barriers
The preventive vaccines market exhibits a highly consolidated structure dominated by multinational pharmaceutical conglomerates with extensive research capabilities and robust manufacturing infrastructure. These established players benefit from significant economies of scale, well-established distribution networks, and long-standing relationships with healthcare providers and government agencies. The market is characterized by high entry barriers due to stringent regulatory requirements, substantial capital investments needed for research and development, and the complexity of vaccine manufacturing processes. Mergers and acquisitions have been prevalent, with larger companies acquiring smaller biotech firms to access innovative technologies and expand their vaccine portfolios.
The competitive landscape is further shaped by the presence of regional players who focus on specific geographic markets or vaccine categories, particularly in emerging economies. These companies often collaborate with global leaders through licensing agreements and technology transfers, contributing to market consolidation. The industry has witnessed increased investment in manufacturing capacity expansion and technological upgrades, particularly in response to the COVID-19 pandemic, leading to enhanced competition in terms of production efficiency and scale.
Innovation and Partnerships Drive Future Success
Success in the preventive vaccines market increasingly depends on companies' ability to innovate in vaccine technologies market, strengthen their manufacturing capabilities, and establish strategic partnerships across the value chain. Incumbent players must focus on developing next-generation vaccines with improved efficacy and safety profiles, while also investing in novel delivery platforms and expanding their presence in emerging markets. The ability to maintain strong relationships with government agencies and international organizations, particularly in light of increasing vaccine nationalism and regulatory scrutiny, will be crucial for maintaining market position.
For new entrants and smaller players, success lies in identifying niche market segments, developing innovative vaccine technologies, and forming strategic alliances with established manufacturers and distributors. Companies must also address the growing emphasis on vaccine accessibility and affordability, particularly in developing regions. The industry's future will be shaped by the ability to respond to emerging infectious diseases, adapt to evolving regulatory requirements, and maintain robust quality control systems. Environmental sustainability in vaccine production and distribution is becoming increasingly important, as is the ability to maintain flexible manufacturing capabilities to respond to sudden demand surges.
Preventive Vaccines Market Leaders
-
Merck & Co
-
GSK plc
-
Johnson & Johnson Services, Inc.
-
Pfizer Inc.
-
Sanofi
- *Disclaimer: Major Players sorted in no particular order

Preventive Vaccines Market News
- April 2024: VBI Vaccines Inc. signed an expansion of its collaboration with the Canadian government, backed by the Strategic Innovation Fund (SIF) funding. The new agreement directed the remaining Canadian USD 28 million from the previously committed Canadian USD 56 million toward developing VBI's proprietary MLE platform. This next-generation platform enhanced the company's eVLP (enveloped virus-like particle) vaccine technology by enabling the coding of eVLPs using messenger RNA (mRNA).
- January 2024: Indian Immunologicals Ltd (IIL), a biopharmaceutical company and a wholly-owned subsidiary of the National Dairy Development Board (NDDB), launched 'Havisure,' India's first indigenously developed Hepatitis A vaccine. This development marked a significant milestone in India's efforts to combat Hepatitis A and is expected to enhance public health significantly.
Preventive Vaccines Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Prevalence of Infectious Diseases
- 4.2.2 Innovative Technology in Vaccine Development
- 4.2.3 Increased Funding from Government and International Organizations
- 4.2.4 Increasing Government Focus on Immunization Programs
-
4.3 Market Restraints
- 4.3.1 Risk of Adverse Effects
- 4.3.2 High Cost of Vaccine Development
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Vaccine Type
- 5.1.1 Live/Attenuated Vaccines
- 5.1.2 Inactivated Vaccines
- 5.1.3 Subunit Vaccines
- 5.1.4 Toxoid Vaccines
- 5.1.5 mRNA Vaccines
- 5.1.6 Other Vaccine Types
-
5.2 By Disease Type
- 5.2.1 Pneumococcal
- 5.2.2 Poliovirus
- 5.2.3 Hepatitis
- 5.2.4 Influenza
- 5.2.5 Measles, Mumps, and Rubella (MMR)
- 5.2.6 COVID-19
- 5.2.7 Other Disease Types
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AstraZeneca PLC
- 6.1.2 Emergent BioSolutions Inc.
- 6.1.3 Daiichi Sankyo Company Limited
- 6.1.4 GSK plc
- 6.1.5 Johnson & Johnson Services, Inc.
- 6.1.6 Merck & Co.
- 6.1.7 Novavax Inc.
- 6.1.8 Pfizer Inc.
- 6.1.9 Sanofi
- 6.1.10 Takeda Pharmaceutical Co. Ltd
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Preventive Vaccines Industry Segmentation
Preventive vaccines are used to prevent infection with viruses, which cause serious diseases. The vaccine is made using a weakened form of the virus that cannot cause disease but causes the body's immune system to make antibodies that destroy the virus.
The preventive vaccines market is segmented by vaccine type, disease type, and geography. By vaccine type, the market is segmented into live/attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, mRNA vaccines, and other vaccine types. By disease type, the market is segmented into pneumococcal, poliovirus, hepatitis, influenza, measles, mumps, and rubella (MMR), COVID-19, and other disease types. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD) for all the above segments.
By Vaccine Type | Live/Attenuated Vaccines | ||
Inactivated Vaccines | |||
Subunit Vaccines | |||
Toxoid Vaccines | |||
mRNA Vaccines | |||
Other Vaccine Types | |||
By Disease Type | Pneumococcal | ||
Poliovirus | |||
Hepatitis | |||
Influenza | |||
Measles, Mumps, and Rubella (MMR) | |||
COVID-19 | |||
Other Disease Types | |||
Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Preventive Vaccines Market Research FAQs
How big is the Preventive Vaccines Market?
The Preventive Vaccines Market size is expected to reach USD 90.78 billion in 2025 and grow at a CAGR of 1.42% to reach USD 97.41 billion by 2030.
What is the current Preventive Vaccines Market size?
In 2025, the Preventive Vaccines Market size is expected to reach USD 90.78 billion.
Who are the key players in Preventive Vaccines Market?
Merck & Co, GSK plc, Johnson & Johnson Services, Inc., Pfizer Inc. and Sanofi are the major companies operating in the Preventive Vaccines Market.
Which is the fastest growing region in Preventive Vaccines Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Preventive Vaccines Market?
In 2025, the North America accounts for the largest market share in Preventive Vaccines Market.
What years does this Preventive Vaccines Market cover, and what was the market size in 2024?
In 2024, the Preventive Vaccines Market size was estimated at USD 89.49 billion. The report covers the Preventive Vaccines Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Preventive Vaccines Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Preventive Vaccines Market Research
Mordor Intelligence provides a comprehensive analysis of the preventive vaccines market. We leverage decades of expertise in global vaccine market research and consulting. Our extensive report covers crucial segments, including human vaccines, viral vaccines, and live attenuated vaccines. There is a particular focus on emerging areas such as COVID-19 vaccination and travel vaccines. The analysis also encompasses recombinant vaccines development and the evolving landscape of hepatitis vaccine technologies. This information is available in an easy-to-download report PDF format.
Our detailed vaccine market analysis offers stakeholders actionable insights into vaccine market trends and precise vaccine market size evaluations. The report provides strategic value to manufacturers, researchers, and healthcare providers. It examines key growth drivers, regulatory frameworks, and technological innovations across the vaccines market. Stakeholders benefit from our thorough vaccine research methodology. This includes primary data collection, expert interviews, and sophisticated forecasting models to deliver accurate market projections and growth opportunities in the preventive vaccines sector.